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Abstract
Background: Source data verification (SDV) is a resource intensive method of quality assurance frequently used in clinical
trials. There is no empirical evidence to suggest that SDV would impact on comparative treatment effect results from a
clinical trial.
Methods: Data discrepancies and comparative treatment effects obtained following 100% SDV were compared to those
based on data without SDV. Overall survival (OS) and Progression-free survival (PFS) were compared using Kaplan-Meier
curves, log-rank tests and Cox models. Tumour response classifications and comparative treatment Odds Ratios (ORs) for the
outcome objective response rate, and number of Serious Adverse Events (SAEs) were compared. OS estimates based on SDV
data were compared against estimates obtained from centrally monitored data.
Findings: Data discrepancies were identified between different monitoring procedures for the majority of variables
examined, with some variation in discrepancy rates. There were no systematic patterns to discrepancies and their impact
was negligible on OS, the primary outcome of the trial (HR (95% CI): 1.18(0.99 to 1.41), p = 0.064 with 100% SDV; 1.18(0.99 to
1.42), p = 0.068 without SDV; 1.18(0.99 to 1.40), p = 0.073 with central monitoring). Results were similar for PFS. More
extreme discrepancies were found for the subjective outcome overall objective response (OR (95% CI): 1.67(1.04 to 2.68),
p = 0.03 with 100% SDV; 2.45(1.49 to 4.04), p = 0.0003 without any SDV) which was mostly due to differing CT scans.
Interpretation: Quality assurance methods used in clinical trials should be informed by empirical evidence. In this empirical
comparison, SDV was expensive and identified random errors that made little impact on results and clinical conclusions of
the trial. Central monitoring using an external data source was a more efficient approach for the primary outcome of OS. For
the subjective outcome objective response, an independent blinded review committee and tracking system to monitor
missing scan data could be more efficient than SDV.
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Introduction
The International Conference on Harmonisation (ICH) Good
Clinical Practice (GCP) guideline [1] defines trial monitoring as
‘‘the act of overseeing the progress of a clinical trial and of
ensuring that it is conducted, recorded and reported in accordance
with the protocol, Standard Operating Procedures, GCP, and the
applicable regulatory requirement(s)’’. The primary aim of trial
monitoring should be to assure patient safety and data quality.
Whilst several approaches exist for monitoring clinical trials, they
are generally classified under the headings of on-site monitoring and
central monitoring.
On-site monitoring includes a range of different procedures for
monitoring, each with a common theme that a member of the
clinical trial team is required to visit one or more of the
participating sites at one or more time points during the trial.
Procedures performed during on-site visits are numerous and may
include checking drug accountability, discussing recruitment and
retention figures for the site, and review of screening logs and
consent forms. One of the most common procedures undertaken
during on-site monitoring is Source Data Verification (SDV), a
procedure that is used to check that data recorded within the trial
Case Report Form (CRF) match the primary source data which
are contained in the relevant source document such as the medical
record of the patient.
Central monitoring also includes a range of different procedures
but is characterised by using centralised procedures instead of site
visits. Procedures may include exploring accumulating data
centrally to check for consistency over time and across different
data items, statistical techniques to identify unusual data patterns
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within and across participating sites, and external validation of
data items, such as through birth and death registries.
ICH GCP is not specific about the format of monitoring in
clinical trials but suggests that ‘‘in general there is a need for on-
site monitoring, before, during and after the trial and the use of
central monitoring in conjunction with other procedures may be
justified in exceptional circumstances’’ [1]. Unfortunately the
guideline is frequently misinterpreted and clinical trials often
routinely include on-site monitoring which can be inefficient,
unnecessary and can result in the already limited resources being
directed at quality assurance procedures that may be unimportant.
Due to a growing concern about the effectiveness and efficiency of
monitoring practices, and a lack of empirical evidence to
determine which practices best achieve the goals of trial
monitoring stated in ICH, the Clinical Trials Transformation
Initiative (CTTI) project on effective and efficient monitoring [2]
was initiated to identify best practices and provide sensible criteria
to help sponsors select the most appropriate monitoring methods
for a clinical trial. One recent output from this project is a survey
of current practice which highlighted the varied approaches to
monitoring and a lack of sufficient empirical evidence to determine
which on-site monitoring practices lead to improved patient safety
and data quality [3]. The CTTI project recommend building
quality in to the trial design and focussing oversight on errors that
are most likely to adversely affect trial quality, recognising that
data elements vary in their impact on the safety of participants or
on the reliability of trial results such that a single-minded focus on
checking/ensuring accuracy of every data point is misguided [2].
Bakobaki et al [4] searched the literature recently and did not
identify any trials that formally evaluated on-site monitoring
techniques or directly compared multiple monitoring strategies
against each other. They subsequently undertook a retrospective
review of a selected sample of on-site monitoring reports from a
large HIV prevention trial, concluding that 95% of the on-site
monitoring findings reviewed could be identified using central
monitoring strategies. Furthermore, Buyse et al [5], Baigent et al
[6] and others have proposed that central monitoring is a more
efficient approach for identification of fraud and anomalies of the
data that are most likely to impact on results. Baigent et al [6]
highlight an example from the Second European Stroke Preven-
tion Study, in which fabricated data on 438 patients from one site
was first detected by central monitoring methods which on-site
monitoring had failed to identify.
The financial, human, and time resource required for on-site
monitoring is greater than for central monitoring and this is likely
to be a significant factor in the choice of approach used by
commercial or non-commercial clinical trials. Results from a
survey of Swedish pharmaceutical companies in 2005 suggested
that fifty percent of the cost of GCP-related activities in phase III
trials was due to SDV, with an estimated actual cost of SDV for a
phase III program estimated as 90 million US Dollars [7]. In a
different study, on-site monitoring was estimated to represent
approximately 25 to 30% of costs in phase III cardiovascular
clinical trials [8]. In 2000, Favalli et al. [9] evaluated the average
cost per site visit in an oncology trial to be 1500 US Dollars not
including the salaries lost through time taken from regular duties.
Due to the high costs associated with site visits and SDV, and
uncertainty about the effectiveness of these approaches, there is an
urgent need to investigate the added value of on-site monitoring in
terms of improving data quality and patient safety. The choice of
monitoring practice should, as far as possible, be based on
empirical evidence which is currently lacking in this important
area.
Data are available from a parallel, open-label, multicentre
(United Kingdom), phase III, superiority RCT comparing control
with experimental treatments in patients with advanced cancer.
The trial was designed and initiated before the introduction of the
United Kingdom (UK) Clinical Regulations in May 2004
(Statutory Instrument 2004 Number 1031) and originally included
a degree of central monitoring for missing and unusual data
identified at each interim analysis and a planned blinded review of
all response data. During the stages of final data collection,
towards the end of the study, the Trial Management Group agreed
to undertake 100% SDV through on-site visits to strengthen
conclusions from the trial by assuring data quality. This paper
describes an empirical comparison of the 100% source verified
data against the corresponding unverified data and explores the
value of SDV for this trial. We also explore the value of centralised
procedures in this setting.
Methods
Between May 2002 and January 2005 the trial recruited 533
patients from 75 secondary and tertiary care centres across the
UK, all of which had research experience but variable in amount.
Patient follow-up and death data were collected and entered on
the trial database up until March 2006. During the conduct of the
trial, all data were collected on paper CRFs and entered onto a
central database. The prospectively planned quality assurance
activities undertaken throughout included a programmed database
designed to minimise input errors (e.g. drop down list rather than
manual input, date checks in relation to dates of entry and
treatments), planned interim analyses (3 interim analyses under-
taken) which included statistical data cleaning of key variables, and
blinded review of response data. This data set will be referred to as
the original data.
After the trial had closed to recruitment but with some patients
in active follow-up, a retrospective monitoring plan was developed
to include 100% SDV of all important identified data items for all
patients to verify that data in the CRF were consistent, complete
and correct when compared with the source such as patient’s
hospital notes. A small team of experienced monitors were
employed to undertake the planned independent SDV activities in
parallel to the trial itself between 2006 and 2007. All source
verified data were re-entered onto a new database, independent to
the original trial database, with manual and computer generated
verification checks. This data set will be referred to as the SDV
data.
Since the SDV was undertaken towards the end of the trial
some of the events observed in the SDV data were due to having
observed a longer patient follow-up compared to the original data.
Therefore, to increase comparability and ensure as far as possible
that any differences observed are due to SDV, a common
‘censoring date’, chosen as the last date of death recorded on the
original database (8/3/06), was used across both data sets. Follow-
up data from the visit prior to this censoring date were used where
relevant in calculations and data recorded after this censoring date
were ignored for the purpose of this empirical comparison. A
sensitivity analysis ignoring this censoring date was also explored
for the primary outcome.
In order to explore the value of SDV in this setting we assessed
whether SDV uncovered data errors related to critical items, but
more importantly whether these data errors affected the main trial
results and related conclusions. Therefore, both data sets were
compared in terms of baseline data, primary outcome (Overall
Survival (OS)), and secondary outcomes (Progression Free Survival
(PFS); Objective response; Serious Adverse Events (SAEs)) of the
Source Data Verification in a Cancer Trial
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e51623
trial. The trial did also collect data for two patient reported
outcomes but SDV has limited value for these outcomes as the
source data are the original patient completed questionnaires
which were routinely returned to the Clinical Trials Unit (CTU).
The following were calculated for each patient using both data
sets:
(i) time from randomisation to death from any cause or last
follow-up for those patients still alive at the common
censoring date
(ii) time from randomisation to progression or death from any
cause, or last follow-up for those patients still alive and
progression free at the common censoring date
(iii) Response assessed in accordance with the World Health
Organization (WHO) criteria for disease response (Response
Evaluation Criteria in Solid Tumors (RECIST)) Guidelines
[10] and reported as best achieved response with criteria
determined as follows:
N Complete response (CR): disappearance of all target lesions
N Partial response (PR): At least a 30% decrease in the sum of
the longest diameter of target lesions, taking as reference the
baseline sum longest diameter
N Stable disease (SD): Neither sufficient shrinkage to qualify for
partial response nor sufficient increase to qualify for
progressive disease, taking as reference the smallest sum
longest diameter since the treatment started
N Progressive disease (PD): At least a 20% increase in the sum
of the longest diameter of target lesions, taking as reference
the smallest sum longest diameter recorded since the
treatment started or the appearance of one or more new
lesions
The number of discrepancies identified are summarised for
clinically relevant baseline characteristics that are typically
reported in randomised controlled trials (RCTs) in this particular
clinical setting. For time-to-event outcomes (OS and PFS), Kaplan
Meier survival curves, log-rank analyses, and unadjusted and
adjusted (adjusted for stratification factors at randomisation for OS
only) Hazard Ratio (HR) estimates with 95% confidence intervals
(CI) obtained from Cox regression models, were compared across
data sets descriptively. For each dataset, overall response was
compared across treatment groups using a chi-square test and by
estimating the Odds Ratio (OR) and 95% CI. A simple
comparison of number of SAEs recorded per patient in each
dataset was undertaken. Differences in recording methods between
datasets made more in-depth comparisons of SAEs difficult.
Central Monitoring for Overall Survival
The Office for National Statistics (ONS) collects registration of
birth and death data which can be made available for research
studies through flagging, provided that the appropriate ethics
approvals are in place. The use of independently collected birth
and death data is a form of central monitoring and is useful to
confirm the existence, date and cause of death for clinical trial
participants.
ONS flagging was not prospectively planned for this study and
so retrospective collection was necessary. A section 60 application
was submitted to the patient information advisory group (PIAG) to
gain approval to collect patient identifiers from participating sites.
The multicentre research ethics committee (MREC) were notified,
and a substantial amendment submitted to the Medicines and
Healthcare products Regulatory Agency (MHRA). Following
these approvals, the NHS number, name, and date of birth were
obtained from participating sites and used for matching by the
ONS. The paper copies of ONS death data were then entered
onto a database by the trial team and verified through double data
entry.
The ONS data provide a further source for the empirical
comparison of the primary outcome OS. Time from randomisa-
tion to ONS date of death, or last follow-up for those patients still
alive at the common censoring date, were calculated and
compared to the original and SDV data using the methods
described above for OS.
Results
Data for all 533 randomised participants were verified against
source data. Discrepancies in baseline characteristics were
detected between the original and SDV data (Table 1). The
percentage of patients with a discrepancy for each characteristic
was generally low and equally distributed across treatment groups
(Table 1) and participating sites (data not shown). In the original
data, 4 patients were identified as ineligible following randomisa-
tion. Three patients had a pre-randomisation CT scan outside the
permitted 30 day interval and one patient had a different cancer
type to that listed as eligible in the protocol. However, the process
of SDV failed to identify these four patients as ineligible which led
to the discrepancy in Table 1. Other than this, there were no
systematic patterns to the direction of discrepancies.
Overall Survival
(i) Comparison of SDV against original data. A total of 13
(2.4%) participants had a discrepancy in date of death between the
SDV and original data. The proportion, magnitude, direction and
type of discrepancy in dates were similar with no systematic
pattern across treatment groups (Table 2) or sites (data not shown),
and suggest that transcription errors were the most likely
explanation in the majority of cases. For a further 29 (5.4%)
participants, the SDV process identified a date of death that had
not been recorded in the original data which raised a discrepancy.
The proportion of these discrepancies were also equally distributed
across treatment groups [15] (5.6%) in control group and 14
(5.2%) in experimental group). All additional deaths identified
through SDV occurred after the last date of follow-up recorded in
the original dataset and were mostly deaths that occurred towards
the end of the trial. The Kaplan Meier survival curve for overall
survival (Figure 1) shows almost identical curves for the original
and SDV data with a negligible effect on the treatment
effectiveness analysis regardless of whether or not adjusted for
stage and performance status (Table 3). Results were almost identical
in a sensitivity analysis using all available SDV data regardless of
the censoring date used in the empirical comparison.
(ii) Comparison of central monitoring (ONS data) versus
SDV. There were 53 (9.9%) discrepancies in date of death
between ONS and SDV data. At the time of final analysis of the
trial data ONS were unable to confirm a date of death for 5 of
these patients. The SDV and original data agreed in four of these
cases and date of death was also subsequently confirmed by site
staff. However, for one of these patients that could not be
confirmed as dead by ONS, original data recorded the patient as
still alive whilst SDV data recorded this patient’s status as ‘still
alive’ but also recorded a date of death (01/04/2005). Although
likely that this patient had died by the time of analysis and thus
should have been included in the ONS data records, we included
the patient as a censored observation in these analyses. For one
Source Data Verification in a Cancer Trial
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further patient, ONS identified a date of death which had not been
recorded in either the SDV or the original data.
The Kaplan Meier survival curve (Figure 1) and unadjusted
treatment effectiveness analysis (Table 3) using centrally monitored
data are almost identical to the SDV and original data analyses.
Progression Free Survival
For the comparison between SDV and original data, there were
a total of 132 patients (24.8%) with a discrepancy in the derived
PFS time (median discrepancy 0.1 months, lower quartile 21.8
months, upper quartile 1.5 months, minimum 213.3 months,
maximum 12.7 months). The percentage of discrepant observa-
tions are similar across treatment groups with no systematic
pattern to the direction or magnitude of discrepancy. The Kaplan
Meier survival curves for PFS (Figure 2) for the SDV and original
data are again almost identical with a negligible effect on the
treatment effectiveness analysis (Table 3).
Response
RECIST response classifications are based on CT scan results
undertaken at specified time points during the trial to assess
change in tumour size from baseline. Across both the SDV ad
original data there were a total of 620 CT scans but only 460
(74.2%) had been assigned a RECIST classification in both data
sets. For these 460 scans, there was agreement in RECIST
classification for 398 (86.5%) but disagreement for 62 (13.5%).
The majority of these disagreements (58 (93.5%)) were due to a
change in classification of one level up or one level down e.g. PD
to SD, with the remaining 4 scans classified as PR in the original
data set but classified as PD in the SDV data. A total of 160 scans
were not common to both datasets; 125 scans which were
identified through SDV and 35 scans that were missed during this
process but which had been recorded in the original data (Table 4).
Information is not available to explore the reason for these
discrepancies. The SDV process is likely to have identified
additional scans that were undertaken outside of the trial protocol
12-week schedule.
To explore how these scan level discrepancies translate to the
patient level overall response analysis, the best achieved response
across all scans was identified for each patient within each dataset.
These response classifications (patient level rather than scan level)
and treatment effectiveness analyses for this outcome were
compared across treatment groups and dataset (Table 5). Although
both datasets suggest a significantly better response rate for
experimental treatment compared to control (lower part of
Table 5), the original data provides a more extreme result (odds
ratio 2.45) in favour of experimental treatment than the SDV data
(odds ratio 1.67). This could suggest a potential bias in the original
dataset as clinicians interpreting scan data were not blind to
treatment allocation and may therefore be more likely to favour a
Table 1. Baseline discrepancies between SDV and original data.
BASELINE CHARACTERISTIC DISCREPANCIES NUMBER OF PATIENTS (%)
CONTROL 266 EXPERIMENTAL 267 TOTAL 533
ELIGIBILITY CRITERIA* 2 (0.8) 2 (0.7) 4 (0.8)
STAGE 8 (3.0) 9 (3.4) 17 (3.2)
WHO PERFORMANCE STATUS 9 (3.4) 7 (2.6) 16 (3.0)
GENDER 2 (0.8) 1 (0.4) 3 (0.6)
DATE OF BIRTH 6 (2.3) 6 (2.2) 12 (2.3)
ETHNIC GROUP 1 (0.4) 6 (2.2) 7 (1.3)
DATE OF DIAGNOSIS 27 (10.2) 26 (9.7) 53 (9.9)
*Four ineligible patients were not identified as ineligible by SDV.
doi:10.1371/journal.pone.0051623.t001
Table 2. Date of death discrepancies between SDV and original data.
Control (n = 266) Experimental (n = 267)
Total discrepancies 5 (1.9%) Total discrepancies 8 (3.0%)
Original Date of death SDV date of death
Days difference
(SDV-original) Original Date of death SDV date of death
Days difference
(SDV-original)
14/12/2002 17/12/2002 3 29/09/2002 24/09/2002 25
15/12/2004 06/01/2005 22 03/10/2003 11/10/2003 8
07/09/2003 07/09/2004 366 26/01/2004 24/01/2004 22
21/08/2004 21/09/2004 31 28/04/2004 26/04/2004 22
25/11/2004 26/11/2004 1 19/12/2003 19/12/2004 366
21/01/2004 02/01/2004 219
29/10/2003 28/10/2003 21
07/02/2005 08/02/2005 1
doi:10.1371/journal.pone.0051623.t002
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better response classification for patients on the experimental
treatment. However, during the trial, all scans were reviewed by a
single clinician unaware of the treatment allocation (original
classification). In addition, the suggestion of bias does not appear
to be supported by the data as the percentage of patients who had
a better response outcome in the SDV data compared to the
original (7.5% on control, 7.6% on experimental), or a worse
response outcome in the SDV compared to the original data (6.7%
on control, 8.9% of patients on experimental) is similar across
treatment groups. These data are based on 134 control and 158
experimental patients with an overall response classification
available in both datasets (data not shown).
Serious Adverse Events
Overall there were 53 patients (9.9%) with a discrepancy in the
number of SAEs between datasets; 20 patients had 29 additional
SAEs recorded in the original dataset and 33 patients had 36
additional SAEs recorded in the SDV data (Table 6). There are
more discrepancies between datasets for patients on control (33
patients with 40 events) compared to experimental (20 patients
Table 3. Treatment effectiveness analysis results – comparison of data sets.
Original SDV Centrally monitored
Overall Survival
HR* (95% CI)
unadjusted
1.18 (0.99 to 1.42) 1.18 (0.99 to 1.41) 1.18 (0.99 to 1.40)
adjusted for stage and performance
status
1.19 (0.99 to 1.43) 1.17 (0.98 to 1.40)
Number of patients 533 533 533
Number of deaths 469 4981 499
Log-rank statistic 3.33 3.44 3.22
Log-rank p-value 0.068 0.064 0.073
Progression Free Survival
HR* (95% CI) 1.29 (1.08 to 1.54) 1.30 (1.09 to 1.54)
Number of patients 5322 5323
Number of events 501 522
Log-rank statistic 7.99 8.76
Log-rank p-value 0.005 0.003
*HR .1 indicates a benefit to experimental treatment.
1Discrepancy in number of deaths between SDV and original data is due to the identification of 29 additional dates of death (all dates occurred before the censoring
date used in this comparison) following source data verification. These patients were censored in the ‘original’ analysis using date of last follow-up.
2Date of progression missing for one patient (id 113).
3Date of progression is before date of randomisation for one patient (id 468).
doi:10.1371/journal.pone.0051623.t003
Figure 1. Kaplan Meier curves comparing SDV, original, and ONS data: Overall Survival.
doi:10.1371/journal.pone.0051623.g001
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with 25 events). This imbalance is not substantial but could suggest
bias in the reporting of SAEs.
Estimated Costs
It is difficult to obtain the full costs of alternative monitoring
approaches for a retrospective analysis such as this. In this
particular example, the main additional financial costs of SDV
would have been for monitors’ salaries and expenses incurred
during the monitoring visits. There were 533 patients recruited
from across 75 sites with an average of 7.1 patients per site.
Assuming it would take an average of 2 hours per patient to
undertake a complete SDV for the overall survival primary
outcome, the process would have taken an estimated 1066 hours,
equivalent to an estimated 30.5 working weeks (7 hours per day, 5
days per week). Assuming an average salary for a clinical trial
monitor of £26,000 per annum (£31,306 annual gross cost), and
an average of £100 per week in expenses, a conservative estimate
of the cost of SDV for the primary outcome is £21,412. The cost
of the alternative central monitoring process was estimated to be
approximately £2,023 to include ONS costs (approximately £500)
and data manager costs (£1523) based on 3 working weeks at
salary of £22,000 per annum (£26,406 annual gross cost) to apply
for section 60 permission, obtain the patient identifiers from site,
submit to ONS (name, date of birth and NHS number where
available – minimum data was name and date of birth),
computerise and validate dates of death. Neither of these estimates
have accounted for the time and financial resources required at
each site which might reasonably be expected to be greater for the
SDV process.
Discussion
Results have been presented for an empirical comparison of
SDV data against original trial data, and also against centrally
monitored data for the primary outcome overall survival. The data
used for this empirical comparison are quite unique as the
comparison relates to a non-commercial clinical trial of an
investigational medicinal product (CTIMP) for which 100% SDV
was performed independently of the main trial. This trial was
initiated prior to EU clinical trials directives and the current UK
Clinical Trial requirements which now require GCP training of
trial staff, Clinical Trial Authorisation and MHRA inspections of
the trial documents as well as site files. Cancer clinical trials in the
UK have also benefited from huge changes in research culture
with the instigation of the National Cancer Research Network.
The current culture of research governance and regulations which
aim to safeguard the quality of clinical trials and safety of patients
would make this particular empirical comparison difficult to repeat
in future.
The comparison identified discrepancies between monitoring
procedures for the majority of variables examined, with some
variation in discrepancy rates. The potential for bias is greatest
when errors are non-random with respect to treatment allocation
[6]. In this example, the identified discrepancies for the baseline
variables and the data required to construct the outcomes OS and
PFS did not differ systematically across treatment groups or across
sites, suggesting that random transcription errors were the most
likely explanation for the majority of variables. For the two time-
Figure 2. Kaplan Meier curves comparing SDV and original data: Progression Free Survival.
doi:10.1371/journal.pone.0051623.g002
Table 4. RECIST response classification for each CT scan
comparing SDV and original data (numbers relate to CT scans
not patients).
SDV classification
CR PR SD PD Missing* Total
Original
classification
CR 5 0 0 0 0 5
PR 1 75 17 4 8 105
SD 0 18 202 17 20 257
PD 0 0 5 116 7 128
Missing* 7 23 48 47 0 125
Total 13 116 272 184 35 620
*No scan result available in the respective data set.
doi:10.1371/journal.pone.0051623.t004
Source Data Verification in a Cancer Trial
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to-event outcomes the effect of these discrepancies on overall
clinical results and conclusions was negligible.
An important, if not surprising finding of this work is that SDV
does not necessarily provide error-free data. In this example, SDV
failed to identify four patients that were classified as ineligible in
the original data. Due to the age and retrospective nature of this
data, we can only speculate that this was due to the monitors’ lack
of clinical knowledge. In reality SDV is an iterative process and so
it is possible that this discrepancy in eligible patients would have
eventually been identified and resolved by the trial team.
However, discrepancies in dates of death were also identified
when SDV data were compared with centrally monitored data
obtained from ONS. It is unlikely that the ONS data would
contain errors but even if it did, these would be expected to occur
completely randomly and be unrelated to the trial, outcome or
treatment and would therefore provide unbiased data for
estimation of the treatment effect. Together with the additional
time and expense of SDV, estimated to be around £19,389, these
findings suggest that the central monitoring procedure of using
ONS data is the optimum approach for assuring the quality of
primary outcome data for this trial.
The analysis of RECIST classification data highlighted impor-
tant issues both in terms of the identification of additional scans,
and in terms of interpretation of scan data. Discrepancies were
most evident, and also had the most impact on results, for this
subjective outcome. The number of additional scans identified
through SDV were similarly distributed across treatment groups
and they most likely reflect the continued clinical monitoring of
patients at sites which were not requested as part of the trial
protocol, or may not have always been fed back to the trials unit.
Furthermore, given that there were discrepancies identified
between SDV and the ONS date of death, and that SDV failed
to identify 4 ineligible patients and 35 scans that were present in
the original dataset, we cannot be certain that the SDV data is
necessarily accurate for this outcome, particularly due to its
subjective nature. It is possible that the monitor assessing the scan
data may not have had the full medical information or knowledge
required to make an accurate clinical assessment, a concern that
has been raised in a previous study [11], as monitors may be less
experienced and knowledgeable in the clinical area compared to
investigators at sites. Alternatively, the clinicians/trial researchers
who made the original assessment may have been biased in some
way because their assessment was unblinded to the patient’s
treatment allocation. However, a second review was undertaken
by a blinded clinician, and the data we explored showed a similar
distribution across treatment groups of the percentage of patients
with an improved response classification between datasets. For this
subjective outcome a robust tracking system for monitoring receipt
of expected scans during the trial, and an independent endpoint
review committee blinded to treatment allocation may have been
the optimal method of quality assurance.
Monitoring approaches were difficult to compare in relation to
SAE data due to the variation in recording and necessary use of
open text fields. However, discrepancies in the number of SAEs
per patient were identified between datasets. This is an important
finding as trial investigators are required to report SAEs to protect
Table 6. Patients with discrepancy in number of Serious Adverse Events.
Number of patients with discrepancy in SAEs
Control (266) Experimental (267) Total (533)
Patients with additional SAEs recorded in original data 13 7 20
Patients with 1 additional event
Patients with 2 additional events
7
6
4
3
11
9
Patients with additional SAEs recorded in SDV data 20 13 33
Patients with 1 additional event
Patients with 2 additional events
19
1
11
2
30
3
Total patients 33 20 53
doi:10.1371/journal.pone.0051623.t006
Table 5. Response analysis comparing SDV and original data (numbers relate to patients).
Original SDV
Control Experimental Control Experimental
(266) (267) (266) (267)
Best achieved response n (%)
CR
PR
SD
PD
CT scan not available
0
26 (9.8)
77 (28.9)
37 (13.9)
126 (47.4)
4 (1.5)
52 (19.5)
71 (26.6)
40 (15.0)
100 (37.5)
1 (0.4)
32 (12.0)
78 (29.3)
52 (19.5)
103 (38.7)
8 (3.0)
43 (16.1)
79 (29.6)
42 (15.7)
95 (35.6)
Overall Response (CR+PR)
OR* (95% CI)
Chi-square test p-value
2.45 (1.49 to 4.04)
0.0003
1.67 (1.04 to 2.68)
0.03
*OR .1 indicates a benefit to experimental treatment.
doi:10.1371/journal.pone.0051623.t005
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patient safety, and a total of 65 additional SAEs were identified
either in the original data that weren’t in the SDV data (29
additional events for 20 patients), or in the SDV data that weren’t
in the original data (36 additional SAEs for 33 patients). Due to the
retrospective nature of this comparison it was not possible to
explore the reason for these discrepancies. It is worth noting that
fewer discrepancies were identified in the experimental group,
possibly due to clinicians’ vigilance identifying and reporting SAEs
for an experimental treatment? Further work is required to assess
the value of SDV for identifying unreported SAEs. However, it is
unlikely that 100% SDV across all patients would be required.
Alternative, risk-proportionate strategies, perhaps focussed on less
experienced sites or those with differing SAE reporting character-
istics compared to other sites, with provision of regular and clear
training, may be more efficient.
SDV is just one of the procedures undertaken during on-site
monitoring and the results presented here should be viewed with
this in mind. There are potentially useful on-site procedures that
have not been explored within this empirical comparison. For
example, the PRIME process [12] used observation by peer
reviewers to improve protocol adherence and train site staff, which
increased trial performance and consistency. As further empirical
research is undertaken, decisions regarding the optimal use of
resources during on-site visits will more likely be evidence based
and risk proportionate. Baigent et al [6] suggest that resources
used for on-site monitoring could be redirected more usefully to
increase sample size, a strategy that may have been particularly
useful in this trial which was originally designed to have 80%
power to detect a difference as statistically significant at the 5%
significance level. Of course, this strategy may not be appropriate
in all trial settings and the ethical implications, and potential
added costs of recruiting additional patients would need to be
considered thoroughly and balanced against the potential gains.
Regulatory agencies have recognised the need for clinical trial
oversight approaches that appropriately account for differing levels
of risk associated with each specific trial. The Medicines and
Healthcare products Regulatory Agency (MHRA) recommend a
risk proportionate approach based on work undertaken by the
MRC/DH/MHRA Joint Project on Risk-adapted Approaches to
the Management of Clinical Trials of Investigational Medicinal
Products [13]. The US Food and Drug Administration (FDA) are
currently developing guidance to assist sponsors of clinical
investigations in developing risk-based monitoring strategies and
plans for investigational studies of medical products. The CTTI
project on Effective and Efficient Monitoring [2] have recently
issued recommendations which include (i) the need to focus on
areas of highest risk for generating errors that matter, (ii)
prospectively measure error rates of important parameters, and
(iii) tailor monitoring approach (e.g., site visits, central, statistical)
to the trial design and key quality objectives. These recent
developments are important advances in clinical trial monitoring
research and reaffirm the need to move away from a one-size fits
all approach of resource intensive and inefficient approaches to
clinical trial monitoring.
To our knowledge the comparison presented in this paper is the
first empirical comparison that has explored the impact of
monitoring method on clinical outcomes and trial conclusions. A
randomised comparison of on-site visits versus no on-site visits has
been attempted and reported in the literature [11]. However, this
trial was terminated early and results could only be used to
evaluate the impact of on-site initiation visits on patient
recruitment, patients’ follow-up time, quantity and quality of data
submitted to the trial coordinating office, none of which were
found to differ between monitoring approaches. The study could
not evaluate the impact of repeated on-site visits on clinical
outcomes. Two further relevant studies are underway. The
ADAMON project [14] is a German led cluster randomised study
involving twelve clinical trials that randomise sites within each trial
to a risk-adapted approach, or to an intensive monitoring strategy
with frequent visits and 100% source data verification. The
OPTIMON project [15] is a French led initiative comparing
intensive monitoring that includes 100% SDV against an
optimized risk-based monitoring approach. Results from both
studies are expected in the next few years and will contribute
important information, along with results from our study, such
that future recommendations regarding monitoring practices may
be more appropriately evidence-based.
Conclusions
The value of the resource intensive source data verification
needs to be established. In this example from cancer the process
was time consuming, expensive, not necessarily error-free, and the
resulting discrepancies identified made no impact on the main
conclusions of the study. Source data verification did identify
additional CT scan data which did impact upon the analysis of a
secondary outcome of overall response. However, further empir-
ical evidence is required to establish its value in this setting as it is
likely that other more efficient methods such as effective tracking
systems for missing scan data and independent blinded review of
CT scans would be sufficient.
In conjunction with a thorough risk-proportionate monitoring
system for the trial, one approach, if ethically reasonable, to
safeguard against the effect of random errors might be to inflate
the target sample size as is often done to account for potential
missing outcome data.
Strengths and Weaknesses
The example presented relates to an academic led, Cancer
Research UK funded trial with short duration and minimal
number lost to follow-up since patients with advanced cancer tend
to stay in follow-up. The trial did not include a per-patient
payment for entering patients and there was no obvious incentive
for fraud. The conclusions drawn may not necessarily apply to
other clinical settings or to commercially funded trials which often
attract significant payments to investigators for entering patients.
However, as long as the potential for errors that are not random in
relation to treatment allocation would not be expected to differ
then the results from this empirical comparison should be
generaliseable to other settings.
As the trial was conducted prior to the 2004 clinical trial
regulations, monitoring practice in CTIMPs may have improved
and the empirical comparison presented here may therefore
represent a worst case scenario which in some respects is a more
informative comparison. As the retrospective SDV was undertaken
towards the end of the trial during which some patients were still
in active follow-up, it is possible that the introduction of this
additional trial process may have changed trial conduct. As this
empirical comparison was not prospectively planned, insufficient
information is available to thoroughly explore and provide
explanations for identified discrepancies. Further confirmatory
empirical studies of this nature are required.
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